Home > Dermatology > EADV 2019 > Emerging Therapies > Biologics: increasingly used in paediatric dermatology

Biologics: increasingly used in paediatric dermatology

Presented By
Prof. Marieke Seyger, Radboud University Nijmegen, the Netherlands
EADV 2019
Biologics and cytokine blockers are increasingly used in children and adolescents with moderate-to-severe psoriasis and atopic dermatitis (AD). Data shows that they cause fewer side effects than systemic conventional therapies [1]. In adults, biologics targeting specific cytokines are effective, well-tolerated, and a safe alternative to conventional systemic treatments. At present, 3 biologics (i.e. etanercept, adalimumab, and ustekinumab) are approved in paediatric psoriasis and dupilumab is approved in AD. TNF-blockers and ustekinumab showed similar efficacy and tolerability compared with trials in an adult population [2-4]. In the meantime, long-term data from open-label extensions with TNF-blockers showed reassuring results. After 5 years, etanercept was still well-tolerated and efficacy was maintained in those who remained in the study for up to 264 weeks [5]. There were no opportunistic infections or malignancies. Similarly, 52-week data from ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on